Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering “gene therapy” treatment: cures could be bad for business in the long run.
“Is curing patients a sustainable business model?” analysts ask in an April 10 report entitled “The Genome Revolution.”
“The potential to deliver ‘one shot cures’ is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies,” analyst Salveen Richter wrote in the note to clients Tuesday. “While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.”
Goldman Sachs asks in biotech research report: ‘Is curing patients a sustainable business model?’
PUBLISHED WED, APR 11 2018
Nothing’s been cured in my lifetime. Nothing. The last thing they cured was polio and that was during the first season of “I Love Lucy.”
At least they’re still working on AIDS. They won’t cure it, but they will figure out a way for you to live with it. They won’t fix it, they’ll just patch it up. Their hope is that one day someone will say, “How come you weren’t at work yesterday?”
“My AIDS is acting up. You know when the weather gets like this, my AIDS just pop up. But I got me some Robitussin and I’m fine now.”
They don’t want to cure anything because the money is in the medicine. It’s like anything else. You think Cadillac can’t make a car that lasts a lifetime? Sure they can. But there’s no money in that.
“We need people to come back. We’ll make a car that lasts seven years. After that, shit’s gonna fall off.”
Diseases are just piling up. People still get cancer, sickle cell, tuberculosis, Jerry’s kids still limping around.
Cure some shit. Get rid of it.
April 19, 2000